Interleukin6 blocking agents for treating COVID19: a living systematic review, Cochrane Library

Authors ' conclusions On average, tocilizumab reduces all ‐cause mortality at D28 compared to standard care alone or placebo and probably results in slightly fewer serious adverse events than standard care alone or placebo. Nevertheless, tocilizumab probably results in little or no increase in the outcome clinical improvement (defined as hospital dischar ge or improvement measured by trialist‐defined scales) at D28. The impact of tocilizumab on other outcomes is uncertain or very uncertain. With the data available, we were not able to explore heterogeneity. Individual patient data meta‐analyses are needed to be able to identify which patients ar e more likely to benefit from this treatment. Evidence for an effect of sarilumab is uncertain and evidence for other anti‐IL6 agents is unavailable. Thirty‐nine RCTs of IL‐6 blocking agents with no results are currently registered, of which nine are completed and seven trials were termi nated with no results available. The findings of this review will be updated as new data are made available on the COVID‐NMA platform ( 2 External 0 0 0covid-nma.com false http://covid-nma.com/ false false%>).
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news